Novel options for the treatment of castration-resistant prostate cancer

Carsten H. Ohlmann; Axel S. Merseburger; Henrik Suttmann; David Schilling; Lutz Trojan; Carsten Kempkensteffen; Stefan Corvin; Michael J. Mathers; Patrick J. Bastian

doi:10.1007/s00345-011-0796-7

Novel options for the treatment of castration-resistant prostate cancer

Carsten H. Ohlmann^*
, Axel S. Merseburger
, Henrik Suttmann
, David Schilling
, Lutz Trojan
, Carsten Kempkensteffen
, Stefan Corvin
, Michael J. Mathers
, Patrick J. Bastian

^*Corresponding author for this work

Department of Urology

Saarland University
University of Tubingen
University of Mannheim
Charite - Universitatsmedizin Berlin
Ludwig-Maximilians-Universität

13 Citations (Scopus)

Abstract

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

Original language	English
Journal	World Journal of Urology
Volume	30
Issue number	4
Pages (from-to)	495-503
Number of pages	9
ISSN	0724-4983
DOIs	https://doi.org/10.1007/s00345-011-0796-7
Publication status	Published - 08.2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

Access to Document

10.1007/s00345-011-0796-7

Cite this

@article{937d0f243f60445f92630bb890dd5b86,

title = "Novel options for the treatment of castration-resistant prostate cancer",

abstract = "Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.",

author = "Ohlmann, \{Carsten H.\} and Merseburger, \{Axel S.\} and Henrik Suttmann and David Schilling and Lutz Trojan and Carsten Kempkensteffen and Stefan Corvin and Mathers, \{Michael J.\} and Bastian, \{Patrick J.\}",

year = "2012",

month = aug,

doi = "10.1007/s00345-011-0796-7",

language = "English",

volume = "30",

pages = "495--503",

journal = "World Journal of Urology",

issn = "0724-4983",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

TY - JOUR

T1 - Novel options for the treatment of castration-resistant prostate cancer

AU - Ohlmann, Carsten H.

AU - Merseburger, Axel S.

AU - Suttmann, Henrik

AU - Schilling, David

AU - Trojan, Lutz

AU - Kempkensteffen, Carsten

AU - Corvin, Stefan

AU - Mathers, Michael J.

AU - Bastian, Patrick J.

PY - 2012/8

Y1 - 2012/8

N2 - Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

AB - Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

UR - https://www.scopus.com/pages/publications/84864569535

U2 - 10.1007/s00345-011-0796-7

DO - 10.1007/s00345-011-0796-7

M3 - Scientific review articles

C2 - 22101903

AN - SCOPUS:84864569535

SN - 0724-4983

VL - 30

SP - 495

EP - 503

JO - World Journal of Urology

JF - World Journal of Urology

IS - 4

ER -

Novel options for the treatment of castration-resistant prostate cancer

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this